Christophe Willekens, MD: Reduced Venetoclax and Azacitidine in AML

preview_player
Показать описание
Dr. Aaron Gerds interviews Dr. Christophe Willekens to discuss his abstract on reduced venetoclax exposure in combination with azacitidine in treatment-naïve acute myeloid leukemia (AML), the results of which were presented at the 64th ASH Annual Meeting and Exposition in New Orleans, Louisiana.
  1. American Society of Hematology
Рекомендации по теме
Christophe Willekens, MD: 0:09:42

Christophe Willekens, MD: Reduced Venetoclax and Azacitidine in AML

Dr. Willekens Presents 0:04:42

Dr. Willekens Presents Efficacy Findings for Reduced-Dose Venetoclax in AML

Phase I trial 0:01:33

Phase I trial results for oral azacitidine and venetoclax in R/R AML

Venetoclax and Azacitidine 0:03:10

Venetoclax and Azacitidine in Newly Diagnosed AML Patients | Dan Pollyea, MD, MS | ASH 2022 #AML

Evaluating long-term survival 0:01:56

Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax

VEN-A-QUI: low-dose cytarabine 0:04:13

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML

The importance of 0:01:08

The importance of predicting venetoclax response in patients with AML

Low-dose azacitidine and 0:02:27

Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML

Novel combinations being 0:04:38

Novel combinations being explored in AML using an HMA-venetoclax backbone

Venetoclax + azacitidine 0:02:43

Venetoclax + azacitidine in unfit patients with AML

Sorafenib or venetoclax 0:02:31

Sorafenib or venetoclax in fractionated busulfan conditioning regimen for AML & MDS

IMGN632 plus venetoclax 0:02:45

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AML

Outcomes of patients 0:02:17

Outcomes of patients with monocytic AML treated with venetoclax & azacitidine

Rationale of OMNIVERSE: 0:01:51

Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML

Dose modification strategies 0:02:42

Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine

What is Venetoclax? 0:09:41

What is Venetoclax? #AML

AML: Managing AEs 0:06:51

AML: Managing AEs With Venetoclax + Azacitidine

The efficacy & 0:02:29

The efficacy & toxicity of venetoclax-based combination therapies in CLL

Combination of Venetoclax 0:05:02

Combination of Venetoclax and Azacitidine To Treat Acute Myeloid Leukemia

AML: options after 0:02:12

AML: options after venetoclax-based regimen failure

allo-SCT improves survival 0:02:16

allo-SCT improves survival following venetoclax and azacitidine therapy in AML

OMNIVERSE: safety and 0:01:24

OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML

Real-world outcomes of 0:02:30

Real-world outcomes of venetoclax + azacitidine versus intensive chemotherapy in newly diagnosed AML

Venetoclax and azacitidine 0:01:40

Venetoclax and azacitidine in older patients with AML